loader
Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of Tezacaftor reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Tezacaftor

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 1Symdeko

    02 2Symdeko

    03 3Symdeko/Symkevi

    04 2Trikafta

    05 3Trikafta/Kaftrio

    PharmaCompass
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Trikafta

    Tezacaftor

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Trikafta

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Vertex

    Tezacaftor

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2019 Revenue in Millions : 420

    2018 Revenue in Millions : 0

    Growth (%) : New launch

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Symdeko

    Tezacaftor

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Symdeko

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Vertex

    Tezacaftor

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2019 Revenue in Millions : 1,418

    2018 Revenue in Millions : 769

    Growth (%) : 84

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Symdeko

    Tezacaftor

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Symdeko

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Vertex

    Tezacaftor

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2020 Revenue in Millions : 629

    2019 Revenue in Millions : 1,418

    Growth (%) : -56

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Trikafta

    Tezacaftor

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Trikafta

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Vertex

    Tezacaftor

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2020 Revenue in Millions : 3,864

    2019 Revenue in Millions : 420

    Growth (%) : 820

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Trikafta/Kaftrio

    Tezacaftor

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Trikafta/Kaftrio

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Vertex

    Tezacaftor

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2021 Revenue in Millions : 5,697

    2020 Revenue in Millions : 3,864

    Growth (%) : 32

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Symdeko/Symkevi

    Tezacaftor

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Symdeko/Symkevi

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Vertex

    Tezacaftor

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2021 Revenue in Millions : 420

    2020 Revenue in Millions : 629

    Growth (%) : -50

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Symdeko/Symkevi

    Tezacaftor

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Symdeko/Symkevi

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Vertex

    Tezacaftor

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2022 Revenue in Millions : 180

    2021 Revenue in Millions : 420

    Growth (%) : -57

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Trikafta/Kaftrio

    Tezacaftor

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Trikafta/Kaftrio

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Vertex

    Tezacaftor

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2022 Revenue in Millions : 7,687

    2021 Revenue in Millions : 5,697

    Growth (%) : 35

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Symdeko/Symkevi

    Tezacaftor

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Symdeko/Symkevi

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Vertex

    Tezacaftor

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2023 Revenue in Millions : 123

    2022 Revenue in Millions : 180

    Growth (%) : -46

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Trikafta/Kaftrio

    Tezacaftor

    arrow
    Discovery on Target
    Not Confirmed

    Brand Name : Trikafta/Kaftrio

    U.S.A
    arrow
    Discovery on Target
    Not Confirmed

    Vertex

    Tezacaftor

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2023 Revenue in Millions : 8,945

    2022 Revenue in Millions : 7,687

    Growth (%) : 14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF